Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809589 | 1.00 | CSNK2A1 (0.36) | CSNK2A1BCDIN3DACHEGRIN2BKDM4E | |
| SCHEMBL2811945 | 0.88 | ACHE (0.38) | ACHEMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL537948 | 0.84 | KDM1A (0.46) | — | |
| SCHEMBL2812302 | 0.83 | ACHE (0.37) | ACHEKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL2808281 | 0.83 | MAPK1 (0.40) | ACHEKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL2809576 | 0.83 | ROCK2 (0.37) | ACHEAPP | |
| SCHEMBL537894 | 0.82 | ALDH1A1 (0.38) | KDM4EALDH1A1SMN1; SMN2TLR7PPARG | |
| SCHEMBL2812997 | 0.82 | FLT3 (0.36) | KDM4EMEN1KMT2AALDH1A1GAA | |
| SCHEMBL2810284 | 0.82 | OGA (0.40) | — | |
| SCHEMBL2814513 | 0.82 | CXCR4 (0.37) | ACHEKDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | CSNK2A1 2365/4885BCDIN3D 1422/4885ACHE 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.